{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"57","value":"41.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"Day 15 of Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"47","value":"88.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"title":"Day 1 of Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"37","value":"157"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"title":"Day 1 of Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28","value":"155"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Day 1 of Cycle 7"},{"categories":[{"measurements":[{"comment":"Geometric Mean and Geometric Coefficient of Variation couldn't be calculated as there were only two participants. Individual values reported:151 µg/mL, 207 µg/mL.","groupId":"OG000","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"Day 1 of Cycle 10"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Cmin was the concentration of study drug in the blood immediately before the next dose was administered. It was measured pre-dose at all visits and was summarized using descriptive statistics.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received the following treatments in a 28-day cycle, continuing until disease progression or a criterion for discontinuation was met.\n\n* Ramucirumab administered intravenously at a dose of 12 mg/kg as a one-hour infusion on days 1 and 15.\n* Cyclophosphamide administered orally at 25 mg/m² daily from days 1 to 28.\n* Vinorelbine administered intravenously at 25 mg/m² on days 1, 8, and 15.","id":"OG000","title":"Ramucirumab + Cyclophosphamide + Vinorelbine"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All randomized participants who received at least one dose of Ramucirumab and had evaluable PK data for this outcome. Number analyzed refers to participants evaluable at specified time points.","reportingStatus":"POSTED","timeFrame":"Prior to ramucirumab infusion on - Day 15 of Cycle 1 and Day 1 of Cycles 2, 4, 7, and 10","title":"PK: Minimum Serum Concentration of Ramucirumab (Cmin)","type":"SECONDARY","unitOfMeasure":"microgram per milliliter (µg/mL)"}